Lupin Launches Topiramate Extended-Release Capsules in the United States

Global pharma major Lupin Limited has announced the launch of Topiramate Extended-Release Capsules in the United States. The product is bioequivalent to the reference listed drug Trokendi XR® Extended-Release Capsules of Supernus Pharmaceuticals, Inc. The capsules are indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older, as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 6 years of age and older, and for the preventive treatment of migraine in patients 12 years of age and older. The estimated annual sale of this product in the U.S. is USD 164 million.